SMG1P3: A Drug Target / Disease Biomarker (G100271836)

Target Name: SMG1P3

NCBI ID: G100271836

SMG1P3

Other Name(s): SMG1 pseudogene 3

SMG1P3: A Drug Target / Disease Biomarker

SMG1P3 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the SMG family of proteins, which are known for their role in intracellular signaling. SMG1P3 has been shown to play a role in a variety of physiological processes, including cell signaling, tissue repair, and inflammation. As a result, SMG1P3 has potential as a drug target or biomarker.

SMG1P3 is involved in a number of signaling pathways that are important for normal brain function. One of the well-studied functions of SMG1P3 is its role in synaptic plasticity, which is the ability of the brain to change and adapt over time. SMG1P3 is a key regulator of synaptic plasticity, and has been shown to play a role in the formation of neural connections in the brain and the regulation of neurotransmitter release.

In addition to its role in synaptic plasticity, SMG1P3 is also involved in the regulation of inflammation. Chronic inflammation is a major risk factor for a variety of diseases, including heart disease and diabetes. SMG1P3 has been shown to play a role in the regulation of inflammation by controlling the production of pro-inflammatory cytokines.

SMG1P3 is also involved in the regulation of cell signaling, which is the process by which cells communicate with one another through the production and reception of signaling molecules. SMG1P3 has been shown to play a role in the regulation of cell signaling by controlling the production of signaling molecules called G-proteins.

In addition to its roles in synaptic plasticity, inflammation, and cell signaling, SMG1P3 is also involved in the regulation of tissue repair. Traumatic injury, burns, and other injuries can result in tissue damage and inflammation, which can lead to chronic pain and other negative consequences. SMG1P3 has been shown to play a role in the regulation of tissue repair by controlling the production of signaling molecules that promote tissue regeneration and the removal of damaged tissue.

SMG1P3 is also a potential biomarker for a variety of diseases. For example, SMG1P3 has been shown to be elevated in the blood of individuals with Alzheimer's disease, a condition characterized by the progressive loss of brain cells and the development of progressive cognitive impairments. Additionally, SMG1P3 has been shown to be elevated in the blood of individuals with other neurological conditions, including multiple sclerosis and amyotrophic lateral sclerosis.

In conclusion, SMG1P3 is a protein that is involved in a variety of physiological processes that are important for normal brain function. As a result, SMG1P3 has potential as a drug target or biomarker. Further research is needed to fully understand the role of SMG1P3 in these processes and to develop effective treatments for a variety of diseases.

Protein Name: SMG1 Pseudogene 3

The "SMG1P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMG1P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets